Enhancing drug development by applying LC-MS-MS for cleaning validation in manufacturing equipment

Pharmaceutical Technology

Volumn 30, Issue 2, 2006, Pages 56-71

  Kolodsick, Kevin J ^a   Phillips, Holly ^a   Feng, Jennifer ^a   Molski, Matthew ^a   Kingsmill, Carol A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEANING; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

DRUG DEVELOPMENTS; DRUG RESIDUES; LC-MS-MS;

BIOMEDICAL ENGINEERING;

ANALYZER; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; REVIEW; STANDARD;

EID: 33646702585     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. International Conference on Harmonization, Q3B: Impurities in New Drug Products (ICH Geneva, Switzerland, Feb. 5, 2003).
2. D.A. LeBlanc, "Establishing Scientifically Justified Acceptance Criteria for Cleaning Validation of APIs" Pharm. Technol. 24 (10), 160-168 (2000).
3. D.A. LeBlanc, "Establishing Scientifically Justified Acceptance Criteria for Cleaning Validation of Finished Drug Products," Pharm. Technol. 22 (10), 136-148 (1998).
4. K.M. Jenkins et al., "Application of Total Organic Carbon Analysis to Cleaning Validation," PDA J. Pharm. Sci. Technol. 50 (1), 6-15 (1996).
5. "Points to Consider for Cleaning Validation-Technical Report No. 29," PDA J. Pharm. Sci. Technol. 52 (6), 1-23 (1998).
6. M.B. Boca, Z. Apostolides, and E. Pretorius, "A Validated HPLC Method for Determining Residues of a Dual Active Ingredient Anti-Malarial Drug on Manufacturing Equipment Surfaces," J. Pharm. Biomed. Anal. 37 (3), 461-468 (2005).
7. M.J. Nozal et al., "Development and Validation of an LC Assay for Sumatriptan Succinate Residues on Surfaces in the Manufacture of Pharmaceuticals," J. Pharm. Biomed. Anal. 30 (2), 285-291 (2002).
8. J. Lambropoulos, G.A. Spanos, and N.V. Lazaridis, "Development and Validation of an HPLC Assay for Fentanyl, Alfentanil, and Sufentanil in Swab Samples," J. Pharm. Biomed. Anal. 23 (2-3), 421-428 (2000).
9. T. Mirza et. al., "Cleaning Level Acceptance Criteria and a High Pressure Liquid Chromatography Procedure for the Assay of Meclizine Hydrochloride Residue in Swabs Collected from Pharmaceutical Manufacturing Equipment Surfaces," J. Pharm. Biomed Anal. 19 (5), 747-756 (1999).
10. T. Mirza et al., "Capillary Gas Chromatographic Assay of Residual Methenamine Hippurate in Equipment Cleaning Validation Swabs," J. Pharm. Biomed. Anal. 16 (6), 939-950 (1998).
11. Z. Katona et al., "Cleaning Validation Procedure Eased by Using Overpressured Layer Chromatography," J. Pharm. Biomed. Anal. 22 (2), 349-353 (2000).
12. R. Debono et al., "Using Ion Mobility Spectrometry for Cleaning Verification in Pharmaceutical Manufacturing." Pharm. Technol. North America 26 (4), 72-78 (2002).
13. F.J. Rowell, Z.F. Miao, and R.N. Neeve, "Pharmaceutical Analysis Nearer the Sampling Point: Use of Simple, Rapid On-Site Immunoassays for Cleaning Validation, Health and Safety, and Environmental Release Applications," J. Pharmacy and Pharmacology 50, 47 (1998).
14. J. Uetrecht, "Prediction of a New Drug's Potential to Cause Idiosyncratic Reactions," Curr. Opin. Drug Discov. Devel. 4 (1), 55-59 (2001).
15. Capsugel, (www.xcelodose.com, Morris Plains, NJ), Accessed Jan. 12, 2006.
16. D.T. Rossi, "The Impact of Atmospheric Pressure Ionization," in Mass Spectrometry in Drug Discovery, D. T. Rossi and M. W. Sinz, Eds. (Marcel Dekker, New York, 2002), pp. 15-24.
17. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng, "Matrix Effect in Quantitative LC-MS-MS Analyses of Biological Fluids: A Method for Determination of Finasteride in Human Plasma at Picogram Per Milliliter Concentrations," Anal. Chem. 70 (5), 882-889 (1998).
18. T.K. Majumdar et al., "Trace Level Quantitation of Iralukast in Human Plasma by Microbore Liquid Chromatography-Tandem Mass Spectrometry," Rapid Commun. Mass Spectrom. 14 (6), 476-481 (2000).
19. K.J. Kolodsick, D.T. Rossi, and C.A. Kingsmill, "Breaking Down Barriers: Can LC-MS Revolutionize the Quantitation of Drug Product Impurities?"LCGC North America 21 (5), 468-479 (2003).
20. J.D. Gilbert, T.V. Olah, and D.A. McLoughlin, "High Performance Liquid Chromatography with Atmospheric Pressure Ionization Tandem Mass Spectrometry as a Tool in Quantitative Bioanalytical Chemistry," in Biochemical and Biotechnological Applications of Electrospray Ionization Mass Spectrometry, P. Snyder Ed. (ACS Symposium Series #619, Washington DC, 1996), pp. 330-350.
21. T.M. Annesley, "Ion Suppression in Mass Spec trometry." Clin. Chem. 49 (7), 1041-1044 (2003).
22. L.E. Sojo, G. Lum, and P. Chee, "Internal Standard Signal Suppression by Co-Eluting Analyte in Isotope Dilution LC-ESI-MS," The Analyst 128 (1), 51-54 (2003).
23. L.R. Snyder, J.J. Kirkland, and J.L. Glajch, Practical HPLC Method Development (Wiley-Interscience, New York, 2nd ed., 1997), pp. 692-693.
24. M.M. Kiser and J. W. Dolan, "Selecting the Best Curve Fit," LCGC Europe 17 (3), 138-143 (2004).
25. International Conference on Harmonization, Q2B: Validation of Analytical Procedures: Methodology (ICH Geneva, Switzerland, Nov. 6, 1996).